ADHD治療薬が自殺・薬物乱用・犯罪のリスクを低下(ADHD medication linked to lower risk of suicide attempts, substance abuse, and criminality)

ad

2025-08-14 カロリンスカ研究所(KI)

スウェーデンのKarolinska Institutetと英サウサンプトン大学の研究で、ADHD(注意欠如・多動症)と診断された約14万8,600人(6~64歳)の医療記録を分析した結果、治療薬の使用が自殺未遂・薬物乱用・交通事故・犯罪のリスク低下と関連することが分かった。ターゲット・トライアル模倣法を用いて治療開始から2年間追跡したところ、自殺未遂は17%、薬物乱用は15%、交通事故は12%、犯罪は13%低下。再発の多い患者では薬物乱用と犯罪が25%減少した(自傷は除く)。これらはADHD薬が症状緩和に加え、生活や社会的リスク軽減にも寄与する可能性を示す重要な結果である。研究成果は、ADHD治療の長期的社会的価値を裏付ける証拠として注目されている。

<関連情報>

ADHD薬物療法と自殺行為、物質乱用、偶然の怪我、交通事故、犯罪のリスク:ターゲット試験のエミュレーション ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials

Le Zhang, postdoctoral researcher,Nanbo Zhu, postdoctoral researcher,Arvid Sjölander, professor,Mikail Nourredine, junior statistician ,Lin Li, postdoctoral researcher,Miguel Garcia-Argibay, senior research fellow,Ralf Kuja-Halkola, statistician,Isabell Brikell, assistant professor,Paul Lichtenstein, professor,Brian M D’Onofrio, professor,Henrik Larsson, professor,Samuele Cortese, professor,Zheng Chang, associate professor
BMJ  Published 13 August 2025
DOI:https://doi.org/10.1136/bmj-2024-083658

ADHD治療薬が自殺・薬物乱用・犯罪のリスクを低下(ADHD medication linked to lower risk of suicide attempts, substance abuse, and criminality)

Abstract

Objective To examine the effects of drug treatment for attention deficit/hyperactivity disorder (ADHD) on suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality.

Design Emulation of target trials.

Setting Linkage of national registers in Sweden, 2007-20.

Participants People aged 6-64 years with a new diagnosis of ADHD, who either started or did not start drug treatment for ADHD within three months of diagnosis.

Main outcome measures First and recurrent events of five outcomes over two years after ADHD diagnosis: suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality.

Results Of 148 581 individuals with ADHD (median age 17.4 years; 41.3% female), 84 282 (56.7%) started drug treatment for ADHD, with methylphenidate being the most commonly prescribed at initiation (74 515; 88.4%). Drug treatment for ADHD was associated with reduced rates of the first occurrence of suicidal behaviours (weighted incidence rates 14.5 per 1000 person years in the initiation group versus 16.9 in the non-initiation group; adjusted incidence rate ratio 0.83, 95% confidence interval 0.78 to 0.88), substance misuse (58.7 v 69.1 per 1000 person years; 0.85, 0.83 to 0.87), transport accidents (24.0 v 27.5 per 1000 person years; 0.88, 0.82 to 0.94), and criminality (65.1 v 76.1 per 1000 person years; 0.87, 0.83 to 0.90), whereas the reduction was not statistically significant for accidental injuries (88.5 v 90.1 per 1000 person years; incidence rate ratio 0.98, 0.96 to 1.01). The reduced rates were more pronounced among individuals with previous events, with incidence rate ratios ranging from 0.79 (0.72 to 0.86) for suicidal behaviours to 0.97 (0.93 to 1.00) for accidental injuries. For recurrent events, drug treatment for ADHD was significantly associated with reduced rates of all five outcomes, with incidence rate ratios of 0.85 (0.77 to 0.93) for suicidal behaviours, 0.75 (0.72 to 0.78) for substance misuse, 0.96 (0.92 to 0.99) for accidental injuries, 0.84 (0.76 to 0.91) for transport accidents, and 0.75 (0.71 to 0.79) for criminality.

Conclusions Drug treatment for ADHD was associated with beneficial effects in reducing the risks of suicidal behaviours, substance misuse, transport accidents, and criminality but not accidental injuries when considering first event rate. The risk reductions were more pronounced for recurrent events, with reduced rates for all five outcomes. This target trial emulation study using national register data provides evidence that is representative of patients in routine clinical settings.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました